Related Experiment Video
Updated: May 11, 2026

Murine Intrapulmonary Tracheal Transplantation: A Model for Investigating Obliterative Airway Disease After Lung Transplantation
Published on: November 10, 2023
Multifocal periostitis as a complication of chronic use of voriconazole in a lung transplant recipient
R Tedja1, A El-Sherief, T Olbrych
1Department of Infectious Disease, Cleveland Clinic Foundation, Cleveland, Ohio 44195, USA. tedjar@ccf.org
Abstract:
Fungal infections are common in solid organ transplantation. An increasing number of transplant recipients receive antifungal therapy for prolonged duration owing to invasive fungal infections. Herein, we describe a diagnosis of periostitis as a complication of chronic use of voriconazole in a lung transplant recipient. The patient was diagnosed with probable pulmonary aspergillosis and was treated with oral voriconazole for a total of 9 months. Evidence of multifocal periostitis was observed in the axial and appendicular skeleton. Early recognition of this phenomenon is important to prevent unnecessary tests and procedures. Prompt discontinuation of voriconazole should result in improvement of symptoms.
Insights
Chronic voriconazole use in lung transplant recipients can lead to periostitis, a bone complication. Early recognition and stopping the antifungal drug can resolve symptoms.
Area of Science:
- Transplantation medicine
- Mycology
- Pharmacology
Background:
- Fungal infections are a significant concern in solid organ transplant recipients.
- Prolonged antifungal therapy is often required for invasive fungal infections.
Observation:
- A lung transplant recipient developed periostitis after 9 months of oral voriconazole treatment for probable pulmonary aspergillosis.
Findings:
- The patient exhibited multifocal periostitis affecting both the axial and appendicular skeleton.
- Periostitis is identified as a complication of chronic voriconazole use.
Implications:
- Early diagnosis of voriconazole-induced periostitis can prevent unnecessary investigations and procedures.
- Discontinuation of voriconazole is recommended for symptom improvement in such cases.
Related Concept Videos
Chronic Obstructive Pulmonary Disease IV: Clinical Manifestations
Antifungal Agents
Chronic Obstructive Pulmonary Disease
Smoking is a primary risk factor for COPD, with over 80% of patients having a history of it. Patients typically experience progressive dyspnea or labored breathing, frequent coughing, and recurrent pulmonary infections. Many eventually succumb to respiratory failure, characterized by...
Chronic Obstructive Pulmonary Disease III: Chronic Bronchitis Features
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
Chronic Obstructive Pulmonary Disease-II: Pathophysiology
Chronic Inflammation